Sugi Predict

Sugi Predict / Compounds / SCHEMBL2422071

SCHEMBL2422071

SCHEMBL2422071

CC(=O)N1CCN[C@H](C)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BIRC2 Q13490 1/20 0.47
▸ HRH4 Q9H3N8 1/20 0.44
▸ CHRNB2 P17787 4/20 0.43
▸ CHRNA3 P32297 4/20 0.43
▸ CHRNA4 P43681 4/20 0.43
▸ CHRNB3 Q05901 2/20 0.43
▸ CHRNA6 Q15825 2/20 0.43
▸ CHRNB4 P30926 2/20 0.42
▸ CHRNA7 P36544 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ MDM2 Q00987 1/20 0.37
▸ REN P00797 1/20 0.36
▸ CA2 P00918 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2418463 1.00 BIRC2 (0.47) BIRC2HRH4CHRNB2CHRNA3CHRNA4
SCHEMBL2418461 1.00 BIRC2 (0.47) BIRC2HRH4CHRNB2CHRNA3CHRNA4
Hydrochloric Acid SCHEMBL18150389 0.98 BIRC2 (0.46) BIRC2HRH4CHRNB2CHRNA3CHRNA4
Hydrochloric Acid SCHEMBL4223891 0.98 BIRC2 (0.46) BIRC2HRH4CHRNB2CHRNA3CHRNA4
Trifluoroacetic Acid SCHEMBL15105232 0.88 BIRC2 (0.40) BIRC2HRH4CHRNB2CHRNA3CHRNA4
Trifluoroacetic Acid SCHEMBL15105233 0.88 BIRC2 (0.40) BIRC2HRH4CHRNB2CHRNA3CHRNA4
SCHEMBL28120270 0.84 BIRC2 (0.49) BIRC2HRH4CHRNB2CHRNA3CHRNA4
SCHEMBL28048803 0.84 BIRC2 (0.49) BIRC2HRH4CHRNB2CHRNA3CHRNA4
SCHEMBL27957087 0.84 BIRC2 (0.49) BIRC2HRH4CHRNB2CHRNA3CHRNA4
SCHEMBL190024 0.83 BIRC2 (0.47) BIRC2HRH4CHRNB2CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115677730-B 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-11-12 — — CN disclosed
US-20240294550-A1 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF LITTDD MEDICINES LTD (CN) 2024-09-05 — — US disclosed
EP-4378943-A1 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Littdd Medicines Ltd (CN) 2024-06-05 — — EP disclosed
CN-118043325-A 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof 励缔(杭州)医药科技有限公司 2024-05-14 — — CN disclosed
CN-115677730-A 8-oxygen-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof 上海辉启生物医药科技有限公司 2023-02-03 — — CN disclosed
WO-2023005928-A1 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海辉启生物医药科技有限公司 2023-02-02 — — WO disclosed
WO-2023005928-A1 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海辉启生物医药科技有限公司 2023-02-02 — — WO disclosed
EP-3237385-B1 MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER US HEALTH (US) 2021-11-24 — — EP disclosed
EP-2909198-B1 BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY ASTEX THERAPEUTICS LTD (GB) 2020-10-14 — — EP disclosed
US-10160748-B2 Indazolones as modulators of tnf signaling ABBVIE INC. (US) 2018-12-25 — — US disclosed
US-8846656-B2 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators NOVARTIS AG (CH) 2014-09-30 — — US disclosed
US-8846656-B2 Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators NOVARTIS AG (CH) 2014-09-30 — — US disclosed
WO-2013163466-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2013-10-31 — — WO disclosed
US-20130184253-A1 TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS NOVARTIS AG (CH) 2013-07-18 — — US disclosed
WO-2013095275-A1 NOVEL HEPATITIS C VIRUS INHIBITORS MEDIVIR AB (SE) 2013-06-27 — — WO disclosed
WO-2013016197-A1 TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS NOVARTIS AG (CH) 2013-01-31 — — WO disclosed
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES H. LUNDBECK A/S (DK) 2011-09-22 — — US disclosed
WO-2010098145-A1 OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY RAQUALIA PHARMA INC. (JP) 2010-09-02 — — WO disclosed
US-20080146546-A1 Bicyclic and Tricyclic Heteroaromatic Compounds NEUROGEN CORPORATION 2008-06-19 — — US disclosed
US-7326709-B2 Bicyclic and tricyclic heteroaromatic compounds NEUROGEN CORPORATION (US) 2008-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294550-A1 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF ATR, OGG1, ATRIP BIRC2 717/4885HRH4 4767/4885CHRNB2 2288/4885
US-20080146546-A1 Bicyclic and Tricyclic Heteroaromatic Compounds GABBR1, GABBR2, GABRA4 BIRC2 4799/4885HRH4 453/4885CHRNB2 108/4885
US-20110230497-A1 BIOLOGICALLY ACTIVE AMIDES NPY5R, NPY1R, NPY2R BIRC2 4302/4885HRH4 85/4885CHRNB2 450/4885
US-10160748-B2 Indazolones as modulators of tnf signaling TNF, CD40, TNFRSF1A BIRC2 962/4885HRH4 952/4885CHRNB2 2449/4885
US-20130184253-A1 TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS C5AR1, C3AR1, C5AR2 BIRC2 2102/4885HRH4 35/4885CHRNB2 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.